These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36738326)

  • 41. Measuring the effect of elexacaftor/tezacaftor/ivacaftor combination therapy on the respiratory pump in people with CF using dynamic chest radiography.
    FitzMaurice TS; McCann C; Nazareth D; Shaw M; McNamara PS; Walshaw MJ
    J Cyst Fibros; 2022 Nov; 21(6):1036-1041. PubMed ID: 35101365
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials.
    Keogh RH; Cosgriff R; Andrinopoulou ER; Brownlee KG; Carr SB; Diaz-Ordaz K; Granger E; Jewell NP; Lewin A; Leyrat C; Schlüter DK; van Smeden M; Szczesniak RD; Connett GJ
    Thorax; 2022 Sep; 77(9):873-881. PubMed ID: 34556554
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
    Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
    Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acneiform Eruption Following Elexacaftor-Tezacaftor-Ivacaftor Treatment in Patients With Cystic Fibrosis.
    Okroglic L; Sohier P; Martin C; Lheure C; Franck N; Honoré I; Kanaan R; Burgel PR; Carlotti A; Dupin N; Oulès B
    JAMA Dermatol; 2023 Jan; 159(1):68-72. PubMed ID: 36449298
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers.
    Bijvelds MJC; Roos FJM; Meijsen KF; Roest HP; Verstegen MMA; Janssens HM; van der Laan LJW; de Jonge HR
    J Cyst Fibros; 2022 May; 21(3):537-543. PubMed ID: 34922851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis.
    Bihler H; Sivachenko A; Millen L; Bhatt P; Patel AT; Chin J; Bailey V; Musisi I; LaPan A; Allaire NE; Conte J; Simon NR; Magaret AS; Raraigh KS; Cutting GR; Skach WR; Bridges RJ; Thomas PJ; Mense M
    J Cyst Fibros; 2024 Jul; 23(4):664-675. PubMed ID: 38388235
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of highly effective CFTR modulator therapy on digital clubbing in patients with cystic fibrosis.
    Mahlen T; Barton L; Roberts D
    J Cyst Fibros; 2022 Sep; 21(5):861-865. PubMed ID: 35915048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Case Report: When cystic fibrosis, elexacaftor/tezacaftor/ivacaftor therapy, and alpha1 antitrypsin deficiency get together.
    Kinuani R; Ezri J; Kernen Y; Rochat I; Blanchon S
    Front Pediatr; 2024; 12():1378744. PubMed ID: 38655277
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate.
    Ryan KJ; Guimbellot JS; Dowell AE; Reed-Walker KD; Kerstner-Wood CD; Anderson JD; Liu Z; Acosta EP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Dec; 1213():123518. PubMed ID: 36371965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-Ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    medRxiv; 2023 Nov; ():. PubMed ID: 37645804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum.
    Habler K; Kalla AS; Rychlik M; Bruegel M; Teupser D; Nährig S; Vogeser M; Paal M
    Clin Chem Lab Med; 2022 Jan; 60(1):82-91. PubMed ID: 34668357
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?
    Niedermayr K; Gasser V; Rueckes-Nilges C; Appelt D; Eder J; Fuchs T; Naehrlich L; Ellemunter H
    Ther Adv Chronic Dis; 2022; 13():20406223221108627. PubMed ID: 35959505
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.
    Egan ME
    Curr Opin Pediatr; 2020 Jun; 32(3):384-388. PubMed ID: 32374578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tezacaftor and ivacaftor for the treatment of cystic fibrosis.
    Paterson SL; Barry PJ; Horsley AR
    Expert Rev Respir Med; 2020 Jan; 14(1):15-30. PubMed ID: 31626570
    [No Abstract]   [Full Text] [Related]  

  • 55. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
    Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
    Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy.
    Zaher A; ElSaygh J; Elsori D; ElSaygh H; Sanni A
    Cureus; 2021 Jul; 13(7):e16144. PubMed ID: 34268058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor.
    Gómez-Ganda L; Galván-Blasco P; Fernández-Polo A; Cardona V; García-Palop B; Parramón-Teixidó CJ; Polverino E; Álvarez-Fernández A
    Front Pharmacol; 2024; 15():1392986. PubMed ID: 38933680
    [No Abstract]   [Full Text] [Related]  

  • 59. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor.
    Fajac I; Daines C; Durieu I; Goralski JL; Heijerman H; Knoop C; Majoor C; Bruinsma BG; Moskowitz S; Prieto-Centurion V; Van Brunt K; Zhang Y; Quittner A
    J Cyst Fibros; 2023 Jan; 22(1):119-123. PubMed ID: 36114142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.
    Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M
    Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.